Lv31
400 积分 2025-01-07 加入
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
1小时前
待确认
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
4个月前
已完结
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer
5个月前
已完结
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
5个月前
已完结
PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations
5个月前
已完结
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis
5个月前
已完结
Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial
5个月前
已关闭
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer
5个月前
已完结
Clarifying the role of SONIA: supporting academic evidence on CDK4/6 inhibitor timing
5个月前
已完结
Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113–08113 LungTech Phase II Trial Results
5个月前
已完结
皖公网安备34019202002308
